Tocilizumab is useful for coronavirus disease 2019 patients: the key point is timing.

Objective: In coronavirus disease 2019, a rapidly progressive inflammatory process is considered to be the main cause of organ damage and mortality. Therefore, the importance of anti-inflammatory treatments such as tocilizumab is increasing.

Methods: A total of 107 patients who received tocilizumab between March 2020 and March 2021 were included in the study.